Form 8-K - Current report:
SEC Accession No. 0001723128-25-000014
Filing Date
2025-03-06
Accepted
2025-03-06 16:16:28
Documents
13
Period of Report
2025-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20250301.htm   iXBRL 8-K 27858
  Complete submission text file 0001723128-25-000014.txt   152651

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20250301.xsd EX-101.SCH 1876
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20250301_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20250301_pre.xml EX-101.PRE 12599
15 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20250301_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 25715462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)